|1.||Hays, J Taylor: 12 articles (01/2014 - 07/2006)|
|2.||Ebbert, Jon O: 10 articles (06/2014 - 04/2008)|
|3.||Evins, A Eden: 7 articles (04/2015 - 06/2008)|
|4.||Williams, Kathryn E: 7 articles (12/2010 - 07/2006)|
|5.||Croghan, Ivana T: 6 articles (01/2014 - 03/2009)|
|6.||Rollema, Hans: 6 articles (01/2014 - 10/2009)|
|7.||Cahill, Kate: 6 articles (01/2013 - 01/2008)|
|8.||Lancaster, Tim: 6 articles (01/2013 - 01/2008)|
|9.||Billing, Clare B: 6 articles (11/2008 - 07/2006)|
|10.||George, Tony P: 5 articles (04/2015 - 06/2010)|
|1.||Tobacco Use Disorder (Nicotine Dependence)
05/01/2006 - "Phase II and III trials have yielded promising results suggesting that varenicline could be an important advance in the treatment of nicotine dependence."
09/01/2009 - "Varenicline, an alpha4beta2-nicotinic partial agonist, is effective for nicotine dependence. "
12/01/2012 - "We explored the relationship between the Fagerström Test for Nicotine Dependence (FTND) and smoking abstinence rates in 10 randomized, double-blind placebo-controlled Phase 2-4 varenicline studies. "
12/01/2011 - "Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline."
03/01/2011 - "This study evaluated abstinence and psychiatric outcomes of various tobacco dependence medications, including varenicline. "
|2.||Chronic Obstructive Pulmonary Disease (COPD)
01/01/2014 - "Varenicline is the newest drug on the market and has been shown to be effective in the general smoking population and in smokers with COPD. "
12/01/2011 - "A recent clinical trial demonstrated the efficacy of varenicline versus placebo as an aid to smoking cessation in patients with COPD. "
01/01/2014 - "Although recent studies have not confirmed such an association, further research is needed given the large number of smokers who are being prescribed varenicline, including important subgroups such as smokers with COPD who may be particularly vulnerable to side effects of drugs. "
12/01/2011 - "A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease."
11/01/2011 - "This paper discusses the results of a randomized, placebo-controlled study evaluating the effects of a smoking cessation intervention including varenicline in patients with COPD. "
|3.||Substance Withdrawal Syndrome (Withdrawal Symptoms)
01/15/2009 - "In the varenicline period, compared with placebo, withdrawal symptoms (p = .04), smoking urges (p < .001), and negative affect (p = .01) during manditory abstinence were significantly lower, and levels of positive affect (p = .046), sustained attention (p = .018), and working memory (p = .001) were significantly greater. "
01/01/2009 - "In the trials, varenicline significantly reduced craving and other withdrawal symptoms. "
08/01/2008 - "The outcomes of this trial established that abstinence from smoking was greater and craving, withdrawal symptoms and smoking satisfaction were less at the end of treatment with varenicline than with transdermal NRT. "
02/01/2015 - "Increasing varenicline dose in smokers with low response to the drug had no significant effect on tobacco withdrawal symptoms or smoking cessation. "
01/01/2015 - "The pharmacokinetics (PK) and pharmacodynamics (PD) of a single 2mg dose of varenicline were investigated in 40 smokers in a randomized, crossover study comparing the effect of varenicline with placebo on ameliorating abstinence-and cue-induced craving and withdrawal symptoms. "
|4.||Acquired Immunodeficiency Syndrome (AIDS)
07/01/2008 - "Preliminary data indicate that varenicline is more effective than other available pharmacologic smoking cessation aids. "
01/01/2015 - "This study reports data from a formative evaluation of a text messaging intervention being developed to increase adherence to smoking cessation medication (varenicline) among tobacco-dependent persons with HIV/AIDS. "
03/01/2013 - "Varenicline is one of the first-line smoking cessation aids recommended in many Clinical Practice Guidelines and its efficacy and safety have been demonstrated in several clinical trials. "
04/01/2007 - "This article reviews current first-line smoking cessation aids and evaluates the clinical trials pertaining to the efficacy and safety of varenicline. "
08/01/2015 - "This brief report analyzes correlates of adherence to varenicline among people living with HIV/AIDS. "
12/01/2009 - "Varenicline is the most effective medication for smoking cessation but does not prevent weight gain. "
01/01/2009 - " found no evidence that varenicline significantly reduced post-cessation weight gain at end of treatment and no follow-up data are currently available. "
11/01/2013 - "Twelve months after the end of SCT, age 50 and over (OR = 0.38, 95% CI [0.19, 0.76]) and varenicline use (OR = 0.30, 95% CI [0.11, 0.78]) were protected against marked weight gain, whereas presence of a comorbidity (OR = 3.33, 95% CI [1.10, 10.00]), high level of nicotine dependence at baseline (OR = 2.07, 95% CI [1.09, 3.92]), and successfully quitting smoking (OR = 4.57, 95% CI [1.94, 10.08]) were associated with marked weight gain. "
07/01/2014 - "Varenicline is more effective in attenuating weight gain than nicotine patch 12 months after the end of smoking cessation therapy: an observational study in Japan."
07/01/2014 - "Our results indicated that varenicline is more effective in attenuating weight gain than nicotine patch in smokers who received Japanese SCT."
|4.||Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
|5.||nicotinic receptor alpha4beta2
|8.||Angiotensin Receptor Antagonists
|10.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|1.||Drug Therapy (Chemotherapy)
|2.||Self Administration (Administration, Self)
|5.||Nebulizers and Vaporizers (Inhaler)